BioBridge offers a variety of ways for you to stay connected with us. You can read our latest press releases or the Annual Reports. Visit the Events Page to find out what’s coming up. You can watch a video clip from a newscast, view past events in the Photo Gallery or read industry news. For the Social Media enthusiast, BioBridge Global is known as “Connect for Life,” and can be found on FacebookTwitterLinkedIn and YouTube. Also visit the official BioBridge Global blog here.

Media is welcome to contact the Corporate Communications Department for more information. We offer:

Interviews with experts in their respective medical fields
  • Interviews with Life Links - community members touched by the services of BioBridge Global
  • Informative tours of the facility
Please contact: 
Corporate Communications
Phone: (210) 731-5519
Mobile: (210) 296-9026

Recent News Articles

Recognition due to advancing large-scale manufacturing capabilities for clinical-grade adult stem cells for research and new therapies
March 10, 2020

BioBridge Global has been named one of two Prototype of the Year Award winners by the Medical Technology Enterprise Consortium (MTEC) for work done following a $7.8 million MTEC grant for the development of large-scale manufacturing capabilities for clinical-grade adult stem cells.

The award was presented at the MTEC Annual Meeting on March 4.

“This award recognizes flawless execution – on-time or ahead of schedule and on-budget for all milestones,” said Becky Cap, Chief Operating Officer of GenCure. “Getting to this point with four collaborators is a huge acknowledgement of excellence both for our execution teams and the supporting groups who worked through billing and reporting requirements.”

Approved for treatment of actively bleeding patients when conventional platelets are not available, or their use is not practical
February 28, 2020

On February 21, 2020, the U.S. Food and Drug Administration has granted the South Texas Blood & Tissue Center (STBTC) approval to manufacture and distribute cold-stored platelets with a shelf life of 14 days for the treatment of actively bleeding patients when conventional platelets are not available, or their use is not practical. 

Platelets are a key blood component constantly in demand for treating severe bleeding, for example in trauma and maternal hemorrhage patients.   

STBTC, a subsidiary of BioBridge Global, is the first civilian blood center in the United States to receive a supplemental approval to produce cold-stored platelets for use in treating actively bleeding patients through day 14 of storage when conventional platelet products are unavailable, or their use is not practical.

GenCure hosts Be the Cure on Campus registry drive to give hope to blood cancer patients like Reggie
February 27, 2020

The University of Texas at San Antonio students, faculty and staff  can save a life by signing up for the marrow donor registry at the Be the Cure on Campus drive. GenCure, a subsidiary of San Antonio nonprofit BioBridge Global, will have sign-up tables on the Main Campus, March 2-4 from 10 a.m.-4 p.m.

Every person who joins the marrow donor registry gives hope to blood cancer patients like Reggie Campbell, who is fighting leukemia for the third time. Campbell needs a marrow transplant, but finding a donor will be an uphill battle for the local fitness coach and his family.

Second location gives QualTex largest automated testing capability in the United States
February 26, 2020

QualTex Laboratories, a subsidiary of San Antonio-based nonprofit BioBridge Global, has begun testing blood and plasma donations on its second automated track system, expanding its capabilities in its San Antonio laboratory.

The Abbott Accelerator a3600 Laboratory Automation System is just the third installed at a donor testing facility in the United States. There also is one at the QualTex Laboratories facility in Norcross, Georgia. The combined systems give QualTex Laboratories the largest automated testing setup in the country.

Ward Carter, Chief Operating Officer of QualTex Laboratories, said the addition of the automation system in San Antonio benefits both customers and staff.

February 19, 2020


With baseline studies close to completion, the GenCure Biomanufacturing facility at the VelocityTX innovation center is on track to be fully operational in the first quarter of 2020. The cGMP-compliant, contract manufacturing facility allows GenCure, a subsidiary of BioBridge Global, to scale up production of adult stem cells, providing critically needed support to researchers and organization looking to move potential therapies from early phase to late phase clinical trials, and on to commercialization.